Share this article
Share this article
SAN FRANCISCO, Jan. 7, 2021 /PRNewswire/ Nalu Bio, Inc. today announced the successful organic synthesis of CBD (cannabidiol) utilizing its proprietary technology platform, closure of its seed financing, and the successful recruitment of a world-class team of life science and consumer packaged goods professionals to develop and scale the company s innovative technology. Nalu Bio s vision for the organic synthesis and cost-effective mass production of CBD mimics the history of aspirin - the therapeutic value of aspirin for pain relief was uncovered, is now mass-produced in the lab, and has become the most commonly used drug in the world.